mydicar genetically targeted enzyme replacement therapy studied use patients severe heart failure designed increase level sarcoplasmic endoplasmic reticulum calcium atpase found membrane sarcoplasmic reticulum sr gene delivered heart via adenoassociated viral using Î±myosin heavy chain gene promoter cardiac muscle cells also called cardiomyocytes mydicar able direct gene expression heart mydicar testedwhen phase study compared placebo advanced heart failure thus far patients treated mydicar shown reduction risk worsening heart failure compared patients treated normal function heart involves proper coordination contraction relaxation cardiomyocytes proper contraction relaxation depends coordinated rise fall cytosol transporter found membrane sr plays important role cycle removing cytosolic cardiomyocyte pumping back sr relaxation heart diastole restores sr next contraction activity declines patients experiencing latestage heart leads normal amount cytosolic cardiomyocytes diastole also results less remaining sr next contraction heart altered cycling cardiomyocytes ultimately leads improper functioning heart indicating potentially beneficial effect gene therapy using administration mydicar occurs via intracoronary injection drug mydicar delivers gene cardiomyocytes using adenoassociated viralvector cardiomyocytes viral vector insert genome increase expression protein delivering gene via aav beneficial readily infects cardiac tissue produce stable longterm expression delivered aavs also produce less immune response alternative viral vehicles aavs studied multiple patients known cause human proper relaxation heart preparation next contraction depends largely decline cytosol cardiomyocytes diastole along impaired contractility increased level cytosolic increases risk arrhythmias remodeling excess found cytosol leads asynchronous contractions cardiomyocytes causing tachyarrhythmias unusual increase contraction faster beating heart leads hypertrophy increasing size cardiac myocytes heart excess hypertrophy cardiac myocytes leads dysfunction heart affecting ability relax contract administration mydicar increasing functioning assist lessening negative effects increase cytosolic diastole increasing reuptake srcitation needed httpsenwikipediaorgwikimydicar